Let’s talk about immunity and why it’s important to take certain factors into consideration when we look at these studies and maybe why the most recent one on AstraZeneca’s effectiveness on the B.1.351 is a tad bit bothersome. For starters this beauty wasn’t tweeted initially.
See that last bullet point? The one of T-cell immunity. Yeah, that’s vital. Why? The study failed to discuss this aspect. You cannot disregard T-cells in the same breath you are discussing B-cells, vaccines and their respective induced antibody responses. It’s a package deal.
T-cells help protect against severe disease. Their analysis shows 76 out of 87 TCB sites (87%) are NOT impacted by the mutations seen in B.1.351. What does this mean? It means the T-cell response generated by AstraZeneca’s vaccine should be highly effective against this variant.
How are you going to disregard our actual immune systems and their ability to make antibodies for later?
Which may I remind you are DRIVEN by vaccines. They teach our bodies to make antibodies for later, not just during active infection (memory T-cells anyone). That’s immunity!
T-cells stimulate B-cells to make antibodies. Antibodies are just your first line of defense which is what is initiated when you get this vaccine. It’s our T-cells that are responsible for long-term immunity. When antibodies diminish after your initial inoculation, your T-cells-
will tell your B-cells it’s time to produce more antibodies. As long as your T-cells still recognize this virus and inform your B-cells they need to produce antibodies, the vaccine is still doing its job. Antibodies being built up over and over again is nothing new or unique-
to this vaccine, this is how vaccines have always worked. This study does not account for this information concerning T-cell immunity at all and then leaves this last bit til the end of the presentation (go figure). Just a heads up, your TCRs and your BCRs target different parts
of the Coronavirus’ spike protein.
Antibodies can prevent infection, your T cell-responses ensure that those antibodies keep doing their job and they kick in after you're infected OR oh my goodness stop the presses- VACCINATED (how about them apples).
In other words, while robust T-cells responses cannot protect you from a mild or moderate infection sometimes (think cough, sniffles, etc.) they can however proliferate rapidly and prevent the build up of viral load. Psst- you want this to be LOW. VL drives disease severity.
So why am I bothered? Because we have half-baked self-proclaimed (excuse my rudeness) experts stating this vaccine is now 10% effective and instilling panic. I’m here to tell you that is FALSE. So, yes, you and your loved ones who received this vaccine? You’re still protected!
Realize this last comment was towards no one specific. I had heard that numerous media outlets were claiming the “10%.” I wasn’t even sure who had presented initially. I was told this was a leaked screen by FT that had to be presented after the fact. My explanation still stands.
So from what I am being told this morning, South Africa is resuming administering doses of AstraZeneca and lifted their halt, but continuing to study its efficacy closely.
Let me reiterate once more, my comments are towards no one specific, including the original presenter. I said “experts” as in plural. This was a broad statement as several media outlets & “experts” were reporting the “10%” efficacy misinformation. My science still stands.
I wanted to add/adjust my statement earlier concerning South Africa resuming rollout of AstraZeneca’s vaccines. They are administering 100,000 doses and then monitoring in a “stepped manner.” Remember, based on what I discussed above, you are still protected if you received it.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with ❄️ Mac n’ Chise ❄️

❄️ Mac n’ Chise ❄️ Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

10 Feb
Concerning the Oxford/AstraZeneca vaccine front, the World Health Organization is recommending doses are given 8-12 weeks apart, which supports the optimal delayed intervals previously suggested following evidence of robust antibody responses we witnessed in a previous study.
It reference to the South African variant B.1.351 and recent concerns over findings in a previous study, SAGE (UK) says that there is no reason not to recommend its use even in countries where that variant is in circulation. I discuss the reason why that probably is more here.
Lastly, this thread details the study done highlighting the efficacy of the Oxford/AstraZeneca vaccine with optimal delayed dose intervals.
Read 5 tweets
10 Feb
A very encouraging study done on our mRNA vaccines! Pfizer and Moderna vaccines provided strong immune responses against variant B.1.351 first identified in South Africa in those who recovered from previous SARS-CoV-2 infections with a SINGLE dose.
medrxiv.org/content/10.110…
Individuals who were previously infected with SARS-CoV-2 displayed weak neutralizing activity not only against the original strain but variant B.1.351 as well (4-8 months post infection; remember antibodies from natural infection eventually wane over time). However, immunization Image
with a single dose of either mRNA vaccine elicited a robust antibody response that boosted neutralizing titers against the original strain by approximately 1000-FOLD. More importantly, vaccination elicited a robust neutralizing antibody response against B.1.351, although
Read 7 tweets
8 Feb
Something we have been waiting for. Concerning Pfizer’s vaccine, results show key mutations N501Y, 69/70-deletion, D614G, and E484K from variant B.1.1.7 and B.1.351 have little effect on neutralization by sera elicited by two doses of the vaccine.
nature.com/articles/s4159…
The neutralization GMT of the serum panel against the virus with three mutations from B.1.351 (E484K + N501Y + D614G) was slightly lower than the neutralization GMTs against the N501Y virus or the virus with three mutations from the UK variant (Δ69/70 + N501Y + D614G). However,
differences in neutralization GMTs against any of the mutant viruses in this study was small (0.81- to 1.41-fold) as compared to the greater than four-fold differences that have been used to signal potential need for a strain change in influenza vaccines.
Read 7 tweets
7 Feb
Per Fauci, “When we get into March, April, and May, there will be a substantial number of people vaccinated. So, when we get into the summer, we likely will be doing things that we maybe were not able to do at a time when there was the 300,000 and 400,000 new infections a day."
You know what this means right? When the time comes please get vaccinated. More vaccines are getting approved which allows for improved vaccine allocation efforts. With the B.1.1.7 becoming the dominant strain in a several areas around the globe, this is good news for us as we
know all these vaccines sufficiently protect against this variant even with the E484K mutation. This gives us time to update against the B.1.351 variant as it attempts to increase its fitness. We could easily be looking towards some normalcy by late this year. Let’s keep going.
Read 4 tweets
7 Feb
It is important to point out that the Oxford/AstraZeneca vaccine is effective against the B.1.1.7 variant and reduces virus shedding and transmission. With this most likely being the dominate strain, this means their current vaccines are still effective as they update boosters.
From what we have seen, it is evident that B.1.1.7 (UK) is inherently more transmissible when compared to the original strain ( by ~50%), and it may be right to assume when populations are exposed to this variant, it’ll likely become the dominant strain relatively quickly.
We are seeing this happen in many areas. Hear me out. In a sense, this actually works to our advantage as we witness this selective pressure occur. B.1.1.7 may be essentially allowing us time to administer booster vaccinations against this variant and it’s newly added E484K.
Read 14 tweets
6 Feb
Please stop this. You conveniently fail to point out NONE of the MORE than 2,000 patients in this study died or was hospitalized. THIS matters. The purpose of vaccination is to bring the severity down to the level of a benign virus. That’s how this works. Report it correctly.
I’d like to mention this article doesn’t possess any numbers or data either. Please understand, the AZN vaccine may not prevent mild to moderate COVID. So you might face something similar to a flu if you happen to get infected after vaccination. It’s better than the alternative.
ALSO it is a KNOWN fact AstraZeneca/Oxford is currently working on a booster to increase efficacy against the B.1.351 variant. News flash: EVERY single vaccine is, not just this one. Let’s stop this. What you need to know is it is going to help you avoid the hospital and worse.
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!